We have described three potential adenovirus type 5 (Ad5)-based replication-competent cancer gene therapy vectors named KD1, KD3, and VRX-007. All three vectors overexpress an Ad5 protein named Adenovirus Death Protein (ADP, also named E3-11.6 K protein). ADP is required for efficient lysis of Ad5-infected cells and spread of virus from cell to cell, and thus its overexpression increases the oncolytic activity of the vectors. KD1 and KD3 contain mutations in the Ad5 E1A gene that knock out binding of the E1A proteins to cellular p300/CBP and pRB; these mutations allow KD1 and KD3 to grow well in cancer cells but not in normal cells. VRX-007 has wild-type E1A. Here we report that radiation increases the oncolytic activity of KD1, KD3, and VRX-007. This increased activity was observed in cultured cells, and it was not because of radiation-induced replication of the vectors. The combination of radiation plus KD3 suppressed the growth of A549 lung adenocarcinoma xenografts in nude mice more efficiently than radiation alone or KD3 alone. The combination of ADP-overexpressing vectors and radiation may have potential in treating cancer.
D espite all the progress in medical sciences, cancer is still the second most frequent cause of death in North America. Conventional treatments that provide adequate anticancer efficacy often have strong side effects. New hope arose with a better understanding of the molecular mechanisms underlying the progression of neoplastic transformation and the subsequent introduction of cancer gene therapy methods. Anticancer viral gene therapy that used replicating viruses seemed to be particularly promising; vectors based on human adenovirus serotype 5 (Ad5) showed good efficacy and good selectivity for tumor cells. [1] [2] [3] These virus vectors replicate preferentially in tumor cells, and their oncolytic activity is a natural consequence of the lytic life cycle of Ad5.
The tumor-selective replication of oncolytic vectors has been achieved in various ways. One method has been to replace one or more viral transcriptional promoters with a cellular promoter that is active only in tumor cells. In this way, the product(s) of the gene(s) (usually an Ad5 essential early gene) that are driven by the cellular promoter are expressed only in tumor cells, thereby restricting virus replication to those cells. Various promoters have been used so far, including the prostatespecific antigen (PSA), [4] [5] [6] tumor-specific a-fetoprotein (AFP), 7 E2F, 8 osteocalcin, 9, 10 and TCF 11, 12 promoters. In another study, the Ad5 E4 promoter was replaced by the tissue-specific surfactant protein B promoter. 13 Another approach has been to delete some of the viral genes that are necessary for viral replication in normal but not in tumor cells. The first group of such vectors carries a deletion in the gene for the E1B-55 K protein, an early protein that-among many other functions-counteracts the proapoptotic effects of the tumor suppressor p53. [14] [15] [16] Workers who have used this type of vector argued that the vector would not be able to replicate in 'normal' cells that have wild-type p53 because the vector could not negate the antiviral effects of p53. On the other hand, the vector would be able to replicate in cancer cells in which the gene for p53 is mutated. Other research groups questioned the nature of this selectivity, showing that ONYX-015 (dl1520), the prototype of this group of vectors, replicates well in certain cell lines that express p53. [17] [18] [19] [20] Shortly thereafter, Ries et al 21 pointed out that it is a defect in the pathway of p53 signaling and not only necessarily mutant p53 itself that is required for replication of these vectors.
Another group of tumor-selective vectors makes use of the fact that Ad5 needs to deregulate the host cell cycle in order to replicate effectively. [22] [23] [24] Ad5 does that with the help of the E1A protein, which binds members of the pRB family of tumor suppressors as well as the p300/CBP transcriptional coactivators and negates their function. Mutations in E1A that abrogate this binding allow the virus to replicate preferentially in cells with a deregulated cell cycle, that is, mostly in tumor cells in the adult human.
We have previously reported on two Ad vectors, KD1 and KD3, that fall into this latter group of oncolytic Ad vectors. 13, 22 These vectors, besides expressing an E1A protein that is defective in promoting the progression of the cell cycle into S-phase, overexpress the adenovirus death protein (ADP), also named E3-11.6 K. ADP is predominantly an Ad5 late protein that facilitates the lysis of the infected cell and the egress of virus from these cells. 25, 26 We have shown that vectors that overexpress ADP spread from cell to cell faster than wild-type Ad5, and that this enhanced vector spread results in improved oncolytic properties of the vector. 13, 22 In addition to the E1A mutations and enhanced ADP expression, in KD1 and KD3 the E3 genes responsible for the downmodulation of the host immune response are deleted. 22 This latter feature decreases the possibility of runaway vector replication.
Although KD1 and KD3 performed well in tissue culture as well as in tumor xenotransplant experiments, 13 ,22 a review of the literature suggested that in in vitro experiments 15, [27] [28] [29] [30] and especially in a clinical setting 31, 32 the oncolytic effect of tumor-selective replicating Ads can be augmented by the use of concomitant radiation and/or chemotherapy. In this paper, we have examined whether the combination of radiation with Ad5-based vectors that overexpress ADP has an advantage over any of these treatments used alone. Our studies include not only KD1 and KD3, 22 but also a new vector named VRX-007. 33 VRX-007 differs from KD3 only in having a wild-type E1A gene. This virus has a robust cytolytic effect because of overexpression of ADP. 33 
Materials and methods

Cells and viruses
HEK 293 human embryo kidney cells were purchased from Microbix (Toronto, ON), Hep3B human hepatocellular carcinoma, and A549 human lung adenocarcinoma cells were obtained from the ATCC (Bethesda, MD). All three cell lines were cultured in Dulbecco's modified Eagle's medium (DMEM) from GIBCO-BRL (Rockville, MD) containing 10% fetal bovine serum (FBS) at 371C in a CO 2 incubator. Mutant pm734.1, an Ad with two missense point mutations in the adp gene that preclude expression of ADP, was described earlier. 26 Mutant dl1101/1107 (dl01/07) was a kind gift from Stanley Bailey. The construction and characterization of KD1 and KD3 are described elsewhere. 22 Briefly, these vectors contain two small deletions in the E1A gene derived from dl01/07 that knock out binding of E1A proteins to p300/CBP and the pRB family, and they have the E3 region deleted and substituted with the adp gene. With KD1, all E3 genes but adp are deleted; KD3 retains the adp gene as well as the gene for the 12.5 K protein, an E3 protein of unknown function. VRX-007 is identical to KD3 in all respects except that it has a wild-type E1A gene. 33 Vector spread assay A549 or Hep3B cells were cultured in 48-well plates. Some of the plates were irradiated using a 6 MV photon beam produced by a dual-energy Siemens KD linear accelerator or a 220 KV photon beam produced by a PANTAK linear accelerator. The cells were infected with serial dilutions À4 plaque forming units (PFU)/cell) 24 h before or after irradiation, of various viruses. The plates were monitored via phase-contrast microscopy, and at 6-7 days postinfection (p.i.) the cells were stained with crystal violet (1% crystal violet, 10% formaldehyde, 20% ethanol) for 15 min. The excess dye was washed away with tap water and the plates were dried at room temperature.
Quantitation of crystal violet staining
The crystal violet dye was extracted from each well with 0.5 ml of 30% acetic acid. The absorbance of the resulting solution was measured in triplicate at 560 nm using a BioTek 340 (Bio-Tek Instruments, Winoski, VE) plate reader. The readings were averaged and plotted as percentage of mock (100%).
Determination of virus yield
A549 cells in 35 mm Petri dishes were incubated for 1 h with 10 PFU/cell of virus in serum-free medium. Afterwards, the dishes were washed twice with DMEM and then DMEM containing 5% FBS was added. After 24 h incubation, the infected cells were mock-irradiated or irradiated with 3 or 6 Gy of radiation, respectively. The setup was as follows: 54 cm source to Petri dish distance, collimator setting 12 cm Â 16 cm, using a 1.5 cm Lucite plate for build-up material. The radiation rate was 200 mu/min. A single fraction was used in each case. Virus was harvested at 1, 2, 3, and 4 days p.i. by collecting aliquots of the medium. The medium was cleared by lowspeed centrifugation and plaque-titered on 293 cells.
Determination of viral DNA replication
A549 cells in 60 mm Petri dishes were infected for 1 h with 10 PFU/cell of KD3 in serum-free medium. Afterwards, the dishes were washed twice with DMEM and then DMEM containing 5% FBS was added. The cells were immediately mock-irradiated or irradiated with 6 Gy of radiation using the 6 MV photon beam and the settings described above. Total DNA (cellular and viral) was harvested at 24, 36, and 48 h p.i. as described earlier. 13 The resulting DNA was digested with Hind III restriction P-labeled anti-Ad probe generated by the Prime-a-gene labeling system (Promega, Madison, WI) using pFG140, a full-genome Ad5 plasmid clone (Microbix, Toronto, ON) as template. The bands were visualized using the STORM 860 equipment (Molecular Dynamics, Sunnyvale, CA), and two fragments (Hind III-A, Hind III-B) were quantified using ImageQuaNT (Molecular Dynamics) software.
Tumor xenograft experiments
Female nude mice of 5-6 weeks age (Harlan Sprague Dawley, Indianapolis, IN) were injected subcutaneously with 1 Â 10 7 A549 cells into both hind flanks. When the tumors reached 70-100 ml in size, the animals were injected intratumorally with buffer or 5 Â 10 8 PFU of KD3. Half of both groups received 4 Gy of full-body radiation at 24 h p.i. The radiation was fractionated into two equal doses given 8 h apart. The setup was as follows: collimator setting 27 cm Â 40 cm, 100 SSD, with the dose calculated at d max irradiating three cages of nude mice at a time. The rate of radiation was 200 mu/min. The virus injection was repeated on day 36 in the case of the radiated group and on days 36 and 63 in the case of the nonradiated group. Tumor sizes were measured twice weekly using a computer-linked digital caliper (Silvac SA, Crissier, Switzerland) and the Mouser tumor measurement and analysis software (VirRx, Inc., St Louis, MO). Statistical significance was calculated using two-tailed Student's t-test and ANOVA.
Results
Virus infection combined with radiation kills cells more efficiently than either infection or radiation alone, and allows for greater spread of virus A 'vector spread assay' 22 was performed to investigate whether ionizing radiation enhances cell killing by KD1 and KD3. In this assay, cells are infected with decreasing multiplicities of infection (MOI) of virus. Cells infected with high MOI are killed by the input virus, causing strong cytopathic effect (CPE). With cells infected with low MOI of virus (10
À4 PFU/cell), visible CPE can develop only after several infect-release-reinfect cycles. Accordingly, the assay measures the ability of the virus to spread from cell to cell.
To carry out the assay, A549 cells were cultured in two 48-well plates. When the cells reached about 80% confluence, one plate was mock-irradiated and the other was irradiated with a dose of 6 Gy. At 24 h after irradiation, the cells were infected with vehicle (mock) or serial dilutions À4 PFU/cell) of (1) pm734.1, a mutant Ad that does not express ADP but is wild-type in other respects; (2) dl01/07, an Ad mutant that has the same E1A deletions as do KD1 and KD3, is lacking the E3 RIDa, RIDb, and 14.7 K genes as do KD1 and KD3, but expresses wild type levels of ADP; (3) KD1; or (4) KD3. The plates were examined daily using phasecontrast microscopy and were stained with crystal violet at 6 days p.i.
In the nonradiated plate, pm734.1 caused some CPE at an MOI of 10 PFU/cell; dl01/07 produced strong CPE when used at 10 PFU/cell and significant CPE at 1 PFU/ cell (Fig 1a, left panel) . Both KD1 and KD3 destroyed most of the monolayers in the wells infected with 10 À1 PFU/cell of viruses and part of the monolayers in the wells infected with 10 À2 PFU/cell of viruses (KD3 also had an effect at 10 À3 PFU/cell). However, when virus infection was combined with radiation, KD1 and KD3 caused almost complete CPE at an MOI of 10 À3 and very extensive CPE at 10 À4 PFU/cell (Fig 1a, right panel) . This represents 2-3 orders of magnitude of enhancement in the cell-killing potential of KD1 and KD3. Stated another way, to achieve a certain amount of cell destruction, 100 Oncolytic adenovirus vectors and radiation K Toth et al to 1000-fold less virus is required with radiation than without radiation. Radiation (6 Gy) alone did not cause visible CPE; rather, it caused a moderate growth arrest indicated by larger and less numerous cells observed by light microscopy (data not shown).
In repeat experiments, we tested the effect of irradiating the cells at 24 h before infection, and 24 h following infection in Hep3B cells. Similar results were obtained in both cases with KD1 and KD3, and with a vector named VRX-007 (see below) (Fig 1b) .
Effect of radiation on the CPE caused by KD3 or VRX-007 is dose dependent
To determine if the enhancement of cell killing by radiation is dose dependent, the experiment shown in Figure 1a was repeated using doses equal to 0, 1, 2, 4, and 6 Gy of radiation. We also tested the effect of radiation on the CPE induced by VRX-007. VRX-007 is identical to KD3 except that it has a wild-type E1A gene. At 24 h after irradiation, the plates were infected with serial dilutions À4 PFU/cell) of KD3 or VRX-007. At 7 days p.i., the plates were stained with crystal violet. The CPE caused by KD3 or VRX-007 increased gradually with the increase in the dose of radiation (Fig 2a) .
To quantify this effect, A549 cells irradiated with doses of 0, 1.5, 3, or 6 Gy were infected with 10 À3 PFU/cell of KD3 or VRX-007. The plates were stained at 6 days p.i., and the crystal violet dye was extracted from the wells and quantitated by measuring the absorbance of the extracts. The concentration of crystal violet in a well is in linear correlation with the number of surviving cells in that particular well. By setting the concentration of crystal violet in the nonradiated mock sample to 100% cell viability, the cell viability in the other samples can be plotted as a percentage of mock versus the dose of radiation. In the experiment shown in Fig 2b, the ratio of surviving cells decreased linearly as the dose of radiation increased. The slope of this decrease is much steeper with KD3-or VRX-007-infected cells than with mock, reaching practically zero cell viability at the 6 Gy dose level in the case of virus-infected cells compared to about 70% viability with mock-infected cells.
These results indicate that radiation, in the applied dose, has only a moderate effect on cell survival by itself. However, radiation causes a large enhancement in the killing potential of KD3 and VRX-007. This effect is dependent on the dose of radiation.
Radiation does not affect the replication of KD3 or VRX-007
To investigate whether the increased CPE produced by the combination of viral infection and radiation is caused by an increase in viral replication, the virus yield from irradiated and nonirradiated cells was compared. A549 cells were infected with 10 PFU/cell of KD3 or VRX-007, and 24 h later were subjected to 3 or 6 Gy of radiation. Aliquots of 100 ml medium were collected at 1, 2, 3, and 4 days p.i., and the virus yield was determined by plaque assays on 293 cells. Both KD3 (Fig 3a) and VRX-007 (Fig 3b) produced similar yields in nonradiated and radiated cells, finally reaching titers of several times 10 7 PFU/ml in the medium.
To exclude potential effects of radiation on something other than viral replication (eg viral egress), the amount of viral DNA synthesis was determined. A549 cells were mock-infected or infected with 10 PFU/cell of KD3. After 1 h, half the cells were subjected to 6 Gy of radiation. Total DNA was extracted from cells at 24, 36, and 48 h p.i. The DNA samples were digested with Hind III, electrophoresed on an agarose gel, and blotted onto a nitrocellulose membrane. The membrane was probed with À3 PFU/cell. The plates were stained with crystal violet at 6 days p.i. The intensity of staining was quantified by measuring the absorbance of the dye extracted from each individual well. The absorbance value obtained for the nonirradiated mock-infected cells was set at 100% cell viability. The % protein content (as a surrogate for survival) of the other samples was determined by comparing the crystal violet absorbance values of those samples to that of nonirradiated mock.
Oncolytic adenovirus vectors and radiation K Toth et al P-labeled Ad DNA, and the two largest bands were quantified using a PhosphorImager. There was at most a two-fold decrease in the amount of DNA detected in the irradiated samples compared to the nonirradiated ones at all three time points (Fig 4) .
We conclude that the increased CPE caused by the combination of Ad infection and radiation is not a result of increased viral replication.
The combination of intratumoral injection of KD3 and radiation therapy is more effective in suppressing the growth of subcutaneous A549 xenografts in nude mice than injection of KD3 alone or radiation treatment alone (Fig 5) . By this time, tumors in the groups treated with single modality (KD3 injection or radiation only) grew ca 15-fold, pointing out the ability of both methods to slow down the growth of A549 tumor xenografts significantly (treated versus nontreated Po0.01 in both cases). However, when KD3 was applied in combination with radiation therapy, the average tumor growth was less then four-fold (Po0.01 ANOVA, Mock rad. versus KD3 rad. P ¼ 0.05, KD3 alone versus KD3 rad. P ¼ 0.03) (Fig 5) .
We conclude that injection of KD3 combined with radiation therapy has a distinct advantage in suppressing tumor growth than either KD3 alone or radiation alone. It is worth noting that the intratumoral injection of 5 Â 10 8 PFU of KD3 had the same antitumoral effect as 4 Gy of radiation (P ¼ 0.89). The results show that the antitumor efficacy of intratumoral injection of KD3 parallels that of radiation therapy. A significant increase in antitumor effect can be achieved by combining the two modalities. Figure 4 Replication of vector DNA is only slightly affected by radiation. A549 cells were infected with 10 PFU/cell of KD3 and subjected to 0 or 6 Gy of radiation at 1 h p.i. Total cellular DNA was extracted at 24, 36, and 48 h p.i. The amount of viral DNA present in the samples was measured by Southern blotting of Hind III-digested DNA and PhosphorImager quantitation of the two largest DNA bands hybridizing with a 32 P-labeled Ad probe. The average intensity of two fragments is shown; the intensity of the 48 h nonirradiated sample was set at 100 arbitrary units.
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Discussion
The failure rate associated with conventional anticancer therapies (ie radiation and chemotherapy) calls for a novel approach to treat cancer. Conventional radiation therapy and chemotherapy are very toxic and cause significant discomfort to the patient by affecting normal cells as well as cancer cells. Since the dose must be limited to protect normal tissues adjacent to the tumor, cancer cells often survive and eventually become resistant to the treatment. To address this problem, oncologists and radiation oncologists have applied a combination of different modalities that allows for lower doses of individual components, thereby reducing the side effects of radiation and chemotherapy while maintaining the efficacy of the treatment. Following this reasoning, we tested if the combination of our ADP-overexpressing Ad vectors with radiation increased the potency of the vectors. We found that the combined effect of vector treatment and radiation was at least additive of vector or radiation treatment given alone, and that the effect could possibly be synergistic. As a result, it is possible that tumors could be treated with lower doses of vector and radiation.
In our experiments, we could not apply clonogenic survival tests that are commonly used to test the effects of cell-killing treatments on cells, inasmuch as replicating vectors would eventually destroy any outgrowing colony. Therefore, as a surrogate measurement for anticancer activity, we examined the vectors' ability to destroy monolayers of A549 lung adenocarcinoma cells; we found that this ability was greatly enhanced by radiation treatment. A549 cells are relatively resistant to radiation; for example, we never observed cell death after irradiation and even a dose of 12 Gy caused only growth arrest (data not shown). Yet, 2-3 orders of magnitude less vector was sufficient to cause complete CPE in the irradiated as compared to the nonirradiated samples. The time of irradiation relative to infection (ie irradiation 24 h before or 24 h after infection) had no influence on efficacy. The effect was dependent on dose, with nearly complete destruction of the monolayers observed with infection with 10 À3 PFU/cell vector combined with 6 Gy of radiation after 6 days.
The mechanism by which radiation decreases the amount of vector needed to cause CPE is unknown. One possibility could have been that radiation stimulates the replication and spread of the vector; this scenario would explain why so much CPE was observed at low MOI. However, as determined from single-step growth curve and viral DNA replication experiments, the replication of viral vectors was neither enhanced nor significantly impaired by 3 or 6 Gy of radiation. This is in agreement with a previous publication, 29 and probably can be explained by the fact that the small (36 kb) viral genome offers a much smaller target than the cellular genome, and therefore the direct and indirect effects of ionizing radiation affect it to a lesser extent. Another research group reported a significant increase in the burst size of their oncolytic vector after radiation treatment. 30 However, the MOI they used (0.1 PFU/cell) does not allow for synchronous infection; thus the experiment presented by them rather resembles our 'vector spread assay', measuring the speed of infect-release cycles.
The activity of the E1A protein expressed from the vectors could have provided an alternative explanation for the combined effect of vector and radiation. That is, the Ad5 E1A proteins have been reported to sensitize cells to radiation. 34, 35 This sensitization could have been brought about by E1A's ability to downregulate the function of the 26S proteasome. 36 The 26S proteasome is implicated in the degradation of inhibitor of nuclear factor-kB (IkB) kinase (IKK), 37 which in turn leads to the activation of NF-kB, an antiapoptotic transcription factor that is activated by genotoxic insults. 38 The inactivation of this pathway by E1A leads to increased sensitivity to radiation. 35, 39 However, we do not consider that this E1A-type mechanism is likely, because KD1 and KD3 both express E1A proteins that have a deletion in the E1A domain that is necessary for sensitization to radiation. 36 Both KD1 and KD3 with mutant E1A showed CPE in the radiated samples at approximately the same time p.i. as did VRX-007, which has wild-type E1A. Also, E1A is expressed at early times during infection, and lysing the cells before the replication cycle of the virus is completed would result in decreased virus production.
As of now, we can only speculate that in the cellular environment created by radiation, the toxic effects of Oncolytic adenovirus vectors and radiation K Toth et al some proteins expressed late in the replicative cycle are enhanced. The CPE caused by the ADP-minus mutant pm734.1 did not seem to be enhanced proportionally to the CPE caused by viruses expressing wild-type or higher levels of ADP (Fig 1a) . This might point to ADP playing a role in the radiosensitization effect, although this possibility should be further investigated. We reported previously that intratumoral injection of KD1 or KD3 retarded the growth of subcutaneous A549, Hep3B, and H441 tumor xenografts in nude mice. 13, 22 These vectors produced the highest level of oncolytic effect when injected daily during a course of 3-5 days. In combination with radiotherapy, a single dose of 5 Â 10 8 PFU of KD3 kept the growth of A549 tumors under control for more than 60 days. This is a marked improvement over the use any of the two agents alone. A second dose of KD3 extended the antitumor effect to over 80 days, when we had to terminate the experiment because the mock-infected control tumors had become too large. It is worth noting that the two single modalities slowed down tumor growth to the same rate: three doses of KD3 spaced at days 0, 36, and 63 worked equally well as radiation therapy.
In conclusion, the combination of our ADP-overexpressing oncolytic Ad vectors and radiation as anticancer therapy allowed for a much lower effective dose of the two agents than would have been necessary had we used a single modality. This, translated onto a clinical setting, should mean much less side effects and morbidity on the patient. Also, as production of GMP-grade Ad vectors is a costly undertaking, this combination approach would make viral gene therapy more accessible.
